|
| |
agouron.com Pages on BioPortfolio:
BioPortfolio - agouron.com
agouron.com - BioPortfolio. ... BioPortfolio - agouron.com contact may help reduce air oxidation by preventing direct ... Laura Pelletier Agouron . ...
http://www.bioportfolio.com/search/agouron.com.html...
|
BioPortfolio.com - BioWeb OPTIPRANOLOL METIPRANOLOL HYDROCHLORIDE ...
... 1956 AUG CAHN DELAVIRDINE MESYLATE TABLET; ORAL RESCRIPTOR -D- + AGOURON 100MG N20705 001 APR 04, 1997 AUG CRLD -A- 100MG N20705 001 APR 04, 1997 AUG.
...
http://www.bioportfolio.co.uk/OPTIPRANOLOL+METIPRANOLOL+HYDR...
|
BioPortfolio - Agouron Pharmaceuticals Incoporated
Agouron Pharmaceuticals Incoporated - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/251-Agouron_Pharmac...
|
BioPortfolio Biotechnology BioNews : live article
Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=h...
|
BioPortfolio - wyle pharmaseuticals
BioPortfolio - wyle pharmaseuticals Agouron Pharmaceuticals, Inc. American ... http://www.bioportfolio.com/search/agouron.com.html. ...
http://www.bioportfolio.com/search/wyle_pharmaseuticals.html...
|
BioPortfolio - Drug Design
Agouron Pharmaceuticals, Inc. was organized in 1984 to bring a fresh approach to the ... Agouron has developed... www.agouron.com/ View full profile ...
http://www.bioportfolio.com/indepth/Drug_Design.html...
|
BioPortfolio - Agouron Pharmaceuticals Incoporated - Profile
View the current Agouron Pharmaceuticals Incoporated Page on BioPortfolio.com ... Agouron Pharmaceuticals, Inc. was organized in 1984 to bring a fresh ...
http://www.bioportfolio.com/biocorporate/251-Agouron+Pharmac...
|
Ontogen Announces Formation of Oncology Advisory Group
3 Apr 2002 ... Dr. Clendeninn most recently served as Corporate Vice President and Head of Clinical Affairs for Agouron Pharmaceuticals, Inc., ...
http://www.bioportfolio.com/news/ontogen_2.htm...
|
BioPortfolio - Checkpoint 1 kinase (Chk-1)
Fax: +1 858-678-8248, E-mail: poe.hsyu@agouron.com. Introduction: Combination of . ... http://www.bioportfolio.com/search/agouron.com.html. ...
http://www.bioportfolio.com/search/Checkpoint_1_kinase_(Chk-...
|
Biotechnology, Pharmaceutical and Life Science Email addresses for ...
Agouron, 23. Maxygen, 23. Pipeline, 23. Tularik, 23. Bell-Labs, 22. Curagen, 22. TResearch, 22. Axyspharm, 22. Mantraonline, 22. Salick, 22. Tresearch, 22 ...
http://www.bioportfolio.com/advertis/bioemail_company.htm...
|
Results from other life science and pharmaceutical sites:
Pfizer Home | Pfizer: the world's largest research-based ...
28 Oct 2008 ... Pfizer Inc: The world's largest research-based pharmaceutical company. Pfizer Inc discovers, develops, manufactures, and markets leading ...
http://www.pfizer.com/...
|
BioPortfolio - agouron.com
agouron.com - BioPortfolio. ... BioPortfolio - agouron.com contact may help reduce air oxidation by preventing direct ... Laura Pelletier Agouron . ...
http://www.bioportfolio.com/search/agouron.com.html...
|
Agouron Reports Results from Preclinical Testing of Compound For ...
Agouron plans to initiate human clinical studies of AG7088 later this year. Agouron Pharmaceuticals, Inc. is an integrated pharmaceutical company committed
...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
BioPortfolio - Agouron Pharmaceuticals Incoporated
Agouron Pharmaceuticals Incoporated - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/251-Agouron_Pharmac...
|
Agouron Acquires New HIV Protease Inhibitor From Japan Energy ...
Agouron plans to initiate clinical studies of JE-2147, formerly known as KNI-764 , in 1999. Agouron will have exclusive rights to the development and ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
BioPortfolio - wyle pharmaseuticals
BioPortfolio - wyle pharmaseuticals Agouron Pharmaceuticals, Inc. American ... http://www.bioportfolio.com/search/agouron.com.html. ...
http://www.bioportfolio.com/search/wyle_pharmaseuticals.html...
|
Agouron Acquires New Anti-HIV Drug from Shionogi
Agouron will have exclusive rights to the development and commercialization of S -1153 in North America, Europe and many other countries, while Shionogi will ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
De novo Screening - a new approach for lead generation.
E-mail: rose@agouron.com. De novo Screening is the process of computationally generating a target biased virtual library of fragments, docking the fragments
...
http://gateway.nlm.nih.gov/MeetingAbstracts/102225563.html...
|
Pharmacokinetics (PK) of nelfinavir (NFV) after once daily dosing ...
Agouron Pharm. Inc., San Diego, CA 92121. Fax: +1 858-678-8248, E-mail: poe.hsyu @agouron.com. Introduction: Combination of mini-doses (100-200 mg/day) of ...
http://gateway.nlm.nih.gov/MeetingAbstracts/102242566.html...
|
Agouron Reports Results of VIRACEPT Combination Therapy in ...
2 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today announced results from the Pediatric AIDS Clinical Trials Group (PACTG) study 353 of the HIV protease ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
|
